11 August 2021>: Clinical Research
Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center
Jianquan Zhu 1ABCDEF , Yu Zhang 1BC , Meng Wang 1BC , Zhenfa Zhang 1BC , Dongsheng Yue 1BC , Shichang Liu 2BC , Yi Pan 3BC , Changli Wang 1AE*DOI: 10.12659/MSM.930738
Med Sci Monit 2021; 27:e930738
Table 1 Baseline characteristics of patients with squamous cell carcinoma of the lung.
Characteristics | ITT (n=36) | Surgery (n=23) |
---|---|---|
Age (years), median (range) | 58 (45–76) | 58 (45–63) |
Male, (%) | 36 (100) | 23 (100) |
Smoking, (%) | ||
Never | 5 (13.9) | 4 (17.4) |
Former/current | 31 (86.1) | 19 (82.6) |
ECOG performance status, (%) | ||
0 | 17 (47.2) | 13 (56.5) |
1 | 19 (52.8) | 10 (43.5) |
T stage, (%) | ||
T2 | 23 (63.9) | 14 (60.9) |
T3 | 13 (36.1) | 9 (39.1) |
ECOG – Eastern Cooperative Oncology Group; ITT – intention-to-treat. |